BriaCell (BCTX) Therapeutics announced that Bria-OTS has cleared its safety evaluation in the Phase 1/2 monotherapy study and has now transitioned to dosing patients in combination with a checkpoint inhibitor. The first patient has been dosed in the checkpoint inhibitor combination cohort of the ongoing Phase 1/2 study of Bria-OTS in metastatic breast cancer. Bria-OTS, a personalized next-generation version of Bria-IMT-currently in a pivotal Phase 3 trial-is designed to enhance immune responses against tumors. The CPI combination cohort follows the successful completion of a three-patient monotherapy safety run-in. The ongoing study will assess Bria-OTS in combination with a CPI in up to 12 patients with metastatic breast cancer, with safety and objective response rate as primary endpoints. BriaCell also plans to evaluate Bria-OTS+, a further optimized version of the platform, across multiple cancer types including breast and prostate cancers.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Therapeutics Reports Promising Phase 2 Results for Metastatic Breast Cancer Treatment
- BriaCell announces presentation of survival, clinical benefit data at ASCO 2025
- BriaCell Therapeutics Advances in Cancer Immunotherapy with Promising Clinical Results
- BriaCell issues letter to shareholders
- BriaCell’s Phase 3 Data Shows Promise for Metastatic Breast Cancer Treatment